Literature DB >> 17785589

Epigallocathechin-3-gallate in AL amyloidosis: a new therapeutic option?

Werner Hunstein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17785589     DOI： 10.1182/blood-2007-05-089243

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  22 in total

1.  Investigating heart-specific toxicity of amyloidogenic immunoglobulin light chains: A lesson from C. elegans.

Authors:  Luisa Diomede; Paola Rognoni; Francesca Lavatelli; Margherita Romeo; Andrea di Fonzo; Claudia Foray; Fabio Fiordaliso; Giovanni Palladini; Veronica Valentini; Vittorio Perfetti; Mario Salmona; Giampaolo Merlini
Journal:  Worm       Date:  2014-10-30

Review 2.  [Amyloidosis of the heart].

Authors:  A V Kristen; C Röcken
Journal:  Pathologe       Date:  2012-05       Impact factor: 1.011

3.  Therapy effects of green tea in a patient with systemic light-chain amyloidosis.

Authors:  Derliz Mereles; Erich E Wanker; Hugo A Katus
Journal:  Clin Res Cardiol       Date:  2008-03-03       Impact factor: 5.460

4.  Epigallocatechin-3-gallate tolerability and impact on survival in a cohort of patients with transthyretin-related cardiac amyloidosis. A single-center retrospective study.

Authors:  Francesco Cappelli; Raffaele Martone; Giulia Taborchi; Sofia Morini; Simone Bartolini; Paola Angelotti; Silvia Farsetti; Carlo Di Mario; Federico Perfetto
Journal:  Intern Emerg Med       Date:  2018-06-07       Impact factor: 3.397

5.  EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity.

Authors:  Jan Bieschke; Jenny Russ; Ralf P Friedrich; Dagmar E Ehrnhoefer; Heike Wobst; Katja Neugebauer; Erich E Wanker
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-12       Impact factor: 11.205

6.  Extracellular remodeling in patients with wild-type amyloidosis consuming epigallocatechin-3-gallate: preliminary results of T1 mapping by cardiac magnetic resonance imaging in a small single center study.

Authors:  Fabian aus dem Siepen; Sebastian J Buss; Florian Andre; Sebastian Seitz; Evangelos Giannitsis; Henning Steen; Hugo A Katus; Arnt V Kristen
Journal:  Clin Res Cardiol       Date:  2015-02-18       Impact factor: 5.460

7.  Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis.

Authors:  Sohsuke Meshitsuka; Sumito Shingaki; Masatoshi Hotta; Miku Goto; Makoto Kobayashi; Yuuichi Ukawa; Yuko M Sagesaka; Yasuyo Wada; Masanori Nojima; Kenshi Suzuki
Journal:  Int J Hematol       Date:  2016-11-04       Impact factor: 2.490

8.  Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis.

Authors:  Derliz Mereles; Sebastian J Buss; Stefan E Hardt; Werner Hunstein; Hugo A Katus
Journal:  Clin Res Cardiol       Date:  2010-03-10       Impact factor: 5.460

9.  Aggregation of Full-length Immunoglobulin Light Chains from Systemic Light Chain Amyloidosis (AL) Patients Is Remodeled by Epigallocatechin-3-gallate.

Authors:  Kathrin Andrich; Ute Hegenbart; Christoph Kimmich; Niraja Kedia; H Robert Bergen; Stefan Schönland; Erich Wanker; Jan Bieschke
Journal:  J Biol Chem       Date:  2016-12-28       Impact factor: 5.157

Review 10.  Natural compounds may open new routes to treatment of amyloid diseases.

Authors:  Jan Bieschke
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.